Suleiman Massarweh

Summary

Affiliation: University of Kentucky
Country: USA

Publications

  1. ncbi request reprint Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response
    Rachel Schiff
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 9:447S-54S. 2003
  2. doi request reprint Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
    Suleiman Massarweh
    Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
    Cancer Res 68:826-33. 2008
  3. ncbi request reprint Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer
    Suleiman Massarweh
    Department of Internal Medicine and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
    Cancer Res 66:8266-73. 2006
  4. ncbi request reprint A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure
    Suleiman Massarweh
    The Department of Internal Medicine, University of Kentucky, Lexington, KY, USA
    Breast Cancer Res Treat 143:325-32. 2014
  5. doi request reprint A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer
    Suleiman Massarweh
    The Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA
    Breast Cancer Res Treat 129:819-27. 2011
  6. ncbi request reprint Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities
    Suleiman Massarweh
    Department of Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40536, USA
    Clin Cancer Res 13:1950-4. 2007
  7. doi request reprint A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation
    Li Chen
    Markey Cancer Center, University of Kentucky, cc452, 800 Rose Street, Lexington, KY 40536, USA
    Breast Cancer Res Treat 136:565-72. 2012
  8. ncbi request reprint HIV-related Hodgkin's disease with central nervous system involvement and association with Epstein-Barr virus
    Suleiman Massarweh
    Department of Medicine, Division of Oncology Hematology, Ben Taub General Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Hematol 72:216-9. 2003
  9. doi request reprint Resolution of extensive leptomeningeal metastasis and clinical spinal cord compression from breast cancer using weekly docetaxel chemotherapy
    Bethany Wilson
    Department of Internal Medicine, University of Kentucky and Markey Cancer Center, Roach Bldg, cc452, 800 Rose St, Lexington, KY 40536, USA
    Breast Cancer Res Treat 131:343-6. 2012
  10. ncbi request reprint Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
    Jiang Shou
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 96:926-35. 2004

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response
    Rachel Schiff
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 9:447S-54S. 2003
    ..Thus, the interactions of these diverse elements are essential considerations in defining new predictive and therapeutic tools...
  2. doi request reprint Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
    Suleiman Massarweh
    Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
    Cancer Res 68:826-33. 2008
    ..This study provides a rationale to combine HER inhibitors with tamoxifen in clinical studies, even in tumors that do not initially overexpress EGFR/HER2...
  3. ncbi request reprint Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer
    Suleiman Massarweh
    Department of Internal Medicine and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
    Cancer Res 66:8266-73. 2006
    ..Combining endocrine therapy with EGFR/HER-2/neu inhibitors should be tested in clinical breast cancer, but a more complete blockade of EGFR/HER-2/neu may be optimal...
  4. ncbi request reprint A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure
    Suleiman Massarweh
    The Department of Internal Medicine, University of Kentucky, Lexington, KY, USA
    Breast Cancer Res Treat 143:325-32. 2014
    ..Since not all patients experience benefit, and in view of potential toxicities, biomarker examination is critical to help select patients most likely to benefit from this strategy in future studies. ..
  5. doi request reprint A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer
    Suleiman Massarweh
    The Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA
    Breast Cancer Res Treat 129:819-27. 2011
    ..02). RNA microarray data showed a corresponding decrease in the expression of cell cycle genes. These results suggest that AFG was an effective neoadjuvant therapy and consistently reduced proliferation in ER-positive tumors...
  6. ncbi request reprint Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities
    Suleiman Massarweh
    Department of Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40536, USA
    Clin Cancer Res 13:1950-4. 2007
    ....
  7. doi request reprint A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation
    Li Chen
    Markey Cancer Center, University of Kentucky, cc452, 800 Rose Street, Lexington, KY 40536, USA
    Breast Cancer Res Treat 136:565-72. 2012
    ..2, 4.4, and 6.3 %, respectively. Our proposed model can be used to select patients at high-risk of early relapse who could benefit from enrollment on clinical trials with novel therapies designed for this group...
  8. ncbi request reprint HIV-related Hodgkin's disease with central nervous system involvement and association with Epstein-Barr virus
    Suleiman Massarweh
    Department of Medicine, Division of Oncology Hematology, Ben Taub General Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Hematol 72:216-9. 2003
    ..Extranodal presence of Hodgkin's disease in patients with HIV infection is probably related to immunosuppression, and physicians treating this illness should be alert to the potential of unusual sites of involvement...
  9. doi request reprint Resolution of extensive leptomeningeal metastasis and clinical spinal cord compression from breast cancer using weekly docetaxel chemotherapy
    Bethany Wilson
    Department of Internal Medicine, University of Kentucky and Markey Cancer Center, Roach Bldg, cc452, 800 Rose St, Lexington, KY 40536, USA
    Breast Cancer Res Treat 131:343-6. 2012
    ..Studying patterns of disease relapse in patients who had received adjuvant weekly taxanes may provide insights into this hypothesis...
  10. ncbi request reprint Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
    Jiang Shou
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 96:926-35. 2004
    ..We used a breast cancer model system with high expression of AIB1 and HER2 to investigate the possible mechanisms underlying this resistance...
  11. ncbi request reprint Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk
    Suleiman Massarweh
    The Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, Texas 77030, USA
    Endocr Relat Cancer 13:S15-24. 2006
    ..Ongoing clinical trials of endocrine therapy combined with growth factor pathway inhibitors or their downstream signaling elements promise to further improve the present care for breast cancer patients...
  12. pmc Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
    Chad J Creighton
    The Dan L Duncan Cancer Center, Baylor College of Medicine, Room N1230 02, One Baylor Plaza BCM 600, Houston, TX 77030, USA
    Cancer Res 68:7493-501. 2008
    ..Over time, the molecular phenotype of breast cancer can change...
  13. ncbi request reprint Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030 3798, USA
    Clin Cancer Res 11:865s-70s. 2005
    ..This process can be delayed or reversed by simultaneous treatment with growth factor pathway inhibitors. This strategy is now being tested in clinical trials...
  14. ncbi request reprint Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
    Grazia Arpino
    Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Natl Cancer Inst 99:694-705. 2007
    ..We investigated whether blockade of all HER homo- and heterodimer pairs by combined treatment with several inhibitors could more effectively inhibit tumor growth in such models...
  15. ncbi request reprint Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan
    Maher A Sughayer
    Department of Pathology, King Hussein Cancer Center, Amman, 11941, Jordan
    Pathol Oncol Res 12:83-6. 2006
    ....